We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+8.43%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$5.25B
AUM Growth
+$451M
Cap. Flow
+$312M
Cap. Flow %
5.94%
Top 10 Hldgs %
53.61%
Holding
70
New
10
Increased
19
Reduced
1
Closed
8

Top Buys

Rank Stock Value
1
BRKR icon
Bruker
BRKR
+$135M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$106M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$60M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$52.6M
5
ISRG icon
Intuitive Surgical
ISRG
+$51.4M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$351M
2
VTYX
Ventyx Biosciences
VTYX
+$46.5M
3
APYX icon
Apyx Medical
APYX
+$8.21M
4
ALLK
Allakos
ALLK
+$5.9M
5
CSTL icon
Castle Biosciences
CSTL
+$5.87M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
2 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMCR icon
1
Immunocore
IMCR
$1.78B
$362M 6.88%
6,029,633
+379,690
+7% +$21.7M
RCKT icon
2
Rocket Pharmaceuticals
RCKT
$348M
$351M 6.69%
17,687,772
– –
ALNY icon
3
Alnylam Pharmaceuticals
ALNY
$36.3B
$320M 6.09%
1,683,362
– –
AXSM icon
4
Axsome Therapeutics
AXSM
$12.4B
$308M 5.86%
4,284,277
+503,422
+13% +$37.1M
PTCT icon
5
PTC Therapeutics
PTCT
$6.37B
$294M 5.6%
7,235,196
+141,898
+2% +$6.94M
RARE icon
6
Ultragenyx Pharmaceutical
RARE
$2.65B
$249M 4.75%
5,405,089
+1,134,093
+27% +$52.6M
MASI
7
DELISTED
Masimo
MASI
$247M 4.7%
1,501,493
– –
ACAD icon
8
Acadia Pharmaceuticals
ACAD
$4.25B
$234M 4.46%
9,783,249
+1,540,385
+19% +$34.2M
PEN icon
9
Penumbra
PEN
$12.5B
$232M 4.41%
673,371
– –
BRKR icon
10
Bruker
BRKR
$9.2B
$219M 4.16%
2,959,603
+1,772,261
+149% +$135M
ARGX icon
11
argenx
ARGX
$57.4B
$188M 3.58%
482,195
– –
ESTA icon
12
Establishment Labs
ESTA
$2.72B
$171M 3.26%
2,494,138
+105,000
+4% +$7.25M
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$162M 3.08%
4,472,985
+829,871
+23% +$34.2M
TMO icon
14
Thermo Fisher Scientific
TMO
$211B
$151M 2.88%
290,334
– –
PTGX icon
15
Protagonist Therapeutics
PTGX
$8.75B
$150M 2.85%
5,415,514
+814,715
+18% +$20.4M
NTRA icon
16
Natera
NTRA
$37.5B
$127M 2.42%
2,611,783
– –
VCEL icon
17
Vericel Corp
VCEL
$2.3B
$124M 2.35%
3,291,873
– –
CLDX icon
18
Celldex Therapeutics
CLDX
$2.77B
$118M 2.24%
3,463,201
+378,986
+12% +$12.8M
AVDL
19
DELISTED
Avadel Pharmaceuticals
AVDL
$112M 2.14%
6,810,641
+1,068,702
+19% +$13.9M
HZNP
20
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$103M 1.96%
+1,000,000
New +$106M
CYTK icon
21
Cytokinetics
CYTK
$11B
$84M 1.6%
2,574,198
– –
TXG icon
22
10x Genomics
TXG
$5.87B
$81.7M 1.56%
1,462,956
+533,670
+57% +$28.9M
RNAM
23
DELISTED
Avidity Biosciences
RNAM
$74.2M 1.41%
6,689,789
+302,611
+5% +$3.8M
ILMN icon
24
Illumina
ILMN
$29.4B
$70.5M 1.34%
386,785
– –
ISRG icon
25
Intuitive Surgical
ISRG
$121B
$58.1M 1.11%
+170,000
New +$51.4M
1
2 3

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q2 2023 Portfolio in Review

As of Q2 2023, RTW Investments held 70 positions worth $5.25B, up 9.4% from $4.8B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

RTW Investments deployed $312M of net new capital in Q2 2023, opening 10 new positions and adding to 19 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,000,000 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Apyx Medical, an estimated $8.21M trimmed.

  • RTW Investments's largest Q2 2023 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,000,000 shares worth $103M.
  • RTW Investments added most to Bruker in Q2 2023, an estimated $135M increase.
  • RTW Investments's biggest Q2 2023 reduction was Apyx Medical, cutting an estimated $8.21M.
  • RTW Investments fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $351M.
  • RTW Investments's ten largest holdings make up 54% of its $5.25B portfolio in Q2 2023.
  • RTW Investments opened 10 new positions and closed 8 in Q2 2023.
  • RTW Investments's portfolio value rose 9.4% quarter-over-quarter to $5.25B.

Based on RTW Investments's 13F filing for Q2 2023, filed 14 Aug 2023.